company background image
UBX

Unity Biotechnology NasdaqGS:UBX Stock Report

Last Price

US$0.59

Market Cap

US$41.1m

7D

0.7%

1Y

-86.3%

Updated

26 Jun, 2022

Data

Company Financials +
UBX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

UBX Stock Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

Unity Biotechnology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Unity Biotechnology
Historical stock prices
Current Share PriceUS$0.59
52 Week HighUS$4.97
52 Week LowUS$0.57
Beta0.39
1 Month Change-28.16%
3 Month Change-49.21%
1 Year Change-86.31%
3 Year Change-93.75%
5 Year Changen/a
Change since IPO-96.43%

Recent News & Updates

Shareholder Returns

UBXUS BiotechsUS Market
7D0.7%10.3%6.6%
1Y-86.3%-24.3%-18.4%

Return vs Industry: UBX underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: UBX underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is UBX's price volatile compared to industry and market?
UBX volatility
UBX Average Weekly Movement9.4%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: UBX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: UBX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200965Anirvan Ghoshhttps://unitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.

Unity Biotechnology Fundamentals Summary

How do Unity Biotechnology's earnings and revenue compare to its market cap?
UBX fundamental statistics
Market CapUS$41.10m
Earnings (TTM)-US$63.88m
Revenue (TTM)US$4.78m

8.6x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
UBX income statement (TTM)
RevenueUS$4.78m
Cost of RevenueUS$40.94m
Gross Profit-US$36.15m
Other ExpensesUS$27.73m
Earnings-US$63.88m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.92
Gross Margin-755.71%
Net Profit Margin-1,335.37%
Debt/Equity Ratio38.2%

How did UBX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is UBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UBX?

Other financial metrics that can be useful for relative valuation.

UBX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-0.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does UBX's PS Ratio compare to its peers?

UBX PS Ratio vs Peers
The above table shows the PS ratio for UBX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average142.2x
OGEN Oragenics
367.8x-162.1%US$37.2m
BYSI BeyondSpring
40.1x52.2%US$54.1m
AIMD Ainos
61.7xn/aUS$41.9m
TCON TRACON Pharmaceuticals
99.3x74.8%US$34.4m
UBX Unity Biotechnology
8.6x86.3%US$41.1m

Price-To-Sales vs Peers: UBX is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (142.2x).


Price to Earnings Ratio vs Industry

How does UBX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: UBX is good value based on its Price-To-Sales Ratio (8.6x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is UBX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UBX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ratio0.005x

Price-To-Sales vs Fair Ratio: UBX is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of UBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate UBX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate UBX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UBX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-9.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UBX is forecast to have no revenue next year.

High Growth Revenue: UBX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UBX is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Unity Biotechnology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-5.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: UBX is currently unprofitable.

Growing Profit Margin: UBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UBX is unprofitable, and losses have increased over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: UBX has a negative Return on Equity (-126.03%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Unity Biotechnology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: UBX's short term assets ($81.5M) exceed its short term liabilities ($17.9M).

Long Term Liabilities: UBX's short term assets ($81.5M) exceed its long term liabilities ($43.9M).


Debt to Equity History and Analysis

Debt Level: UBX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if UBX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UBX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: UBX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 8.1% each year.


Discover healthy companies

Dividend

What is Unity Biotechnology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as UBX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Anirvan Ghosh (57 yo)

2.25yrs

Tenure

US$3,936,710

Compensation

Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...


CEO Compensation Analysis

Compensation vs Market: Anirvan's total compensation ($USD3.94M) is above average for companies of similar size in the US market ($USD749.40K).

Compensation vs Earnings: Anirvan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: UBX's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: UBX's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.1%.


Top Shareholders

Company Information

Unity Biotechnology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Unity Biotechnology, Inc.
  • Ticker: UBX
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$41.100m
  • Shares outstanding: 69.17m
  • Website: https://unitybiotechnology.com

Number of Employees


Location

  • Unity Biotechnology, Inc.
  • 285 East Grand Avenue
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.